ELAC1 Antibody / Zinc phosphodiesterase ELAC protein 1 Antibody (FY13660)

ELAC1 Antibody by IHC in Human Liver Cancer Tissue. Immunohistochemistry analysis of ELAC1 expression in a paraffin-embedded section of human liver cancer tissue using ELAC1 Antibody. Brown DAB staining is observed in numerous tumor cells, primarily within the cytoplasm, with variable intensity across the tissue section. Hematoxylin counterstaining highlights the blue-purple nuclei. The distribution of immunoreactivity is heterogeneous, with some tumor cells showing stronger staining than neighboring cells.

ELAC1 Antibody by FCM in fixed HEL cells. Flow cytometry analysis of intracellular ELAC1 in HEL cells following fixation with 4% paraformaldehyde and permeabilization. Cells were incubated with ELAC1 Antibody at 1 ug per 1x10^6 cells, followed by a Fluoro488-conjugated goat anti-rabbit IgG secondary antibody. The blue antibody-stained population is shifted to higher fluorescence intensity relative to the green rabbit IgG isotype control and red unstained control. This experiment used fixed, permeabilized cells and does not demonstrate live-cell surface staining.

ELAC1 Antibody by WB in human and rodent lysates. Western blot analysis using ELAC1 Antibody on a 10% SDS-PAGE gel. Lanes 1-6 contain K562, HeLa, PC-3, rat liver, mouse liver and NIH/3T3 lysates, respectively. A major immunoreactive band migrates near 47-50 kDa across all samples, consistent with the expected size of zinc phosphodiesterase ELAC protein 1. Stronger signals are visible in the liver lysates, but lane intensity alone should not be interpreted as quantitative expression. Additional high-molecular-weight bands are present in liver lanes; their identities are not established. Molecular weight markers are shown at left.